Delcath Systems Inc

+0.15 (+4.27%)
7:45:33 PM EDT: $3.74 +0.08 (+2.19%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)38.34M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.85 Million
Adjusted EPS-$0.74
See more estimates
10-Day MA$3.68
50-Day MA$3.46
200-Day MA$3.88
See more pivots

Delcath Systems Inc Stock, NASDAQ:DCTH

1633 Broadway, Suite 22 C, New York, New York 10019
United States of America
Phone: +1.212.489.2100
Number of Employees: 55


Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.